MedTrace Logo

A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases

NCT07357220 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-01-21

No results posted yet for this study

Summary

An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.

Conditions

  • Colorectal Cancer With Hepatic Metastases

Interventions

BIOLOGICAL

VG2025

Recommended Phase II Dose, Intratumoral Injection, Q4W

DRUG

AK112

20mg/kg, ivgtt, Q2W

Sponsors & Collaborators

  • Shanghai Virogin Biotech Co., Ltd.

    collaborator INDUSTRY

  • Akeso

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-02
Primary Completion
2027-02-28
Completion
2028-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07357220 on ClinicalTrials.gov